Desmopressin

DRUG INFORMATION

  ADULT
    - Diabetes Insipidus: The daily dose is 2 mcg to 4 mcg administered as one or two
      divided doses by subcutaneous or intravenous injection.
      Source: US FDA label for desmopressin (Desmopressin Acetate), section 'dosage and
      administration', retrieved 2026-08-29
    - (2.1 ) Hemophilia A and von Willebrand’s Disease (Type I): 0.3 mcg/kg (to a
      maximum of 20 mcg) administered by intravenous infusion.
      Source: US FDA label for desmopressin (Desmopressin Acetate), section 'dosage and
      administration', retrieved 2026-08-29
    - Diabetes Insipidus: Treatment naïve patients: The recommended starting daily
      dosage is 2 mcg to 4 mcg administered as one or two divided doses by subcutaneous
      or intravenous injection.
      Source: US FDA label for desmopressin (Desmopressin Acetate), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - The safety and effectiveness of desmopressin acetate have been established in
      pediatric patients 3 months of age and older with hemophilia A and von
      Willebrand’s disease and pediatric patients aged 12 years and older with diabetes
      insipidus.
      Source: US FDA label for desmopressin (Desmopressin Acetate), section 'pediatric
      use', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - Desmopressin acetate is contraindicated in patients with moderate to severe renal
      impairment (defined as a creatinine clearance below 50 mL/min) [see
      Contraindications ( 4 ), Use in Specific Populations ( 8.6 ), Clinical
      Pharmacology ( 12.3 )].
      Source: US FDA label for desmopressin (Desmopressin Acetate), section 'use in
      specific populations', retrieved 2026-08-29
    - Fluid restriction should be discussed with the patient [see Warnings and
      Precautions ( 5.1 )]. 8.6 Renal Impairment Desmopressin acetate is substantially
      excreted by the kidney, and the risk of adverse reactions may be greater in
      patients with renal impairment than patients with normal renal function.
      Source: US FDA label for desmopressin (Desmopressin Acetate), section 'use in
      specific populations', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for desmopressin (Desmopressin
      Acetate), retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Prolonged experience with desmopressin acetate injection in pregnant
      women over several decades, based on the available published literature and case
      reports, have not identified a drug associated risk of major birth defects,
      miscarriage or other adverse maternal or fetal outcomes.
      Source: US FDA label for desmopressin (Desmopressin Acetate), section 'pregnancy',
      retrieved 2026-08-29
    - In addition, in vitro studies with human placenta demonstrate poor placental
      transfer of desmopressin.
      Source: US FDA label for desmopressin (Desmopressin Acetate), section 'pregnancy',
      retrieved 2026-08-29
    - No adverse developmental outcomes were observed in animal reproductive and
      developmental studies following administration of desmopressin acetate during
      organogenesis to pregnant rats and rabbits, at doses 130- and 110- times,
      respectively, the recommended dose of 18 mcg for a 60 kg patient, based on body
      surface area (mg/m 2 ).
      Source: US FDA label for desmopressin (Desmopressin Acetate), section 'pregnancy',
      retrieved 2026-08-29

  BREASTFEEDING
    - There is no information on the effects of desmopressin on the breastfed child or
      on milk production.
      Source: US FDA label for desmopressin (Desmopressin Acetate), section 'use in
      specific populations', retrieved 2026-08-29
    - The developmental and health benefits of breastfeeding should be considered along
      with the mother’s clinical need for desmopressin acetate injection and any
      potential adverse effects on the breastfed child from desmopressin acetate
      injection or from the underlying maternal condition.
      Source: US FDA label for desmopressin (Desmopressin Acetate), section 'use in
      specific populations', retrieved 2026-08-29
    - Data The breast milk of lactating women was collected over 8 hours following
      administration of 300 mcg desmopressin nasal spray.
      Source: US FDA label for desmopressin (Desmopressin Acetate), section 'use in
      specific populations', retrieved 2026-08-29